IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTERPACE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.00−0.15 (-2.91%)
Close on Oct 19, 2026
- Market cap
- $138.57M
- P/E (TTM)
- 5.6
- Dividend yield
- –
Interpace Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Market Cap | $138.51M | $230.55M |
| Enterprise Value | $135.82M | $202.97M |
| PE Ratio | 5.62 | 31.60 |
| PS Ratio | 3.83 | 3.10 |
| PB Ratio | 5.96 | 3.04 |
| P/TBV Ratio | 5.96 | 4.43 |
| P/FCF Ratio | 33.75 | 27.30 |
| P/OCF Ratio | 31.08 | 22.47 |
Enterprise value
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| EV / Sales | 3.76 | 2.91 |
| EV / EBITDA | 29.27 | 19.74 |
| EV / EBIT | 32.60 | 24.80 |
| EV / FCF | 33.09 | 27.89 |
Income (trailing twelve months)
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Revenue | $36.14M | $102.39M |
| Gross Profit | $23.04M | $60.36M |
| Operating Income | $4.17M | -$4.31M |
| Pretax Income | $4.00M | -$2.37M |
| Net Income | $24.45M | -$6.57M |
| EBITDA | $4.64M | -$1.98M |
| EPS (Diluted) | $0.89 | -$0.08 |
Margins
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Gross Margin | 63.7% | 55.2% |
| Operating Margin | 11.5% | -6.04% |
| Pretax Margin | 11.1% | -4.11% |
| Profit Margin | 67.6% | -10.5% |
| EBITDA Margin | 12.8% | -2.67% |
| FCF Margin | 11.4% | 0.02% |
Returns
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | 221.9% | -18.2% |
| Return on Assets (ROA) | 104.3% | -13.3% |
| Return on Invested Capital (ROIC) | 44.2% | -3.69% |
| Return on Capital Employed (ROCE) | 14.1% | -9.07% |
Growth
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -20.5% | 8.85% |
| Net Income Growth (YoY) | 435.6% | 10.5% |
| Revenue Growth (3Y CAGR) | 6.75% | 7.08% |
| Revenue Growth (5Y CAGR) | 3.63% | 11.8% |
Balance sheet
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.69M | $36.66M |
| Net Cash (Debt) | $2.69M | $3.92M |
| Net Cash Per Share | $0.10 | $0.28 |
| Equity (Book Value) | $23.24M | $55.33M |
| Book Value Per Share | $0.84 | $2.87 |
| Tangible Book Value | $23.24M | $10.79M |
| Working Capital | $6.02M | $56.72M |
Financial position
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Current Ratio | 2.22 | 2.48 |
| Quick Ratio | 1.82 | 1.53 |
Cash flow (trailing twelve months)
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | $4.46M | -$566.22K |
| Capital Expenditures | -$353.00K | -$3.69M |
| Free Cash Flow | $4.10M | -$696.00K |
| FCF Per Share | $0.15 | -$0.02 |
Efficiency
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 1.54 | 0.58 |
| Inventory Turnover | 12.73 | 2.21 |
| Revenue Per Employee | $354.34K | $322.92K |
| Profits Per Employee | $239.68K | -$51.88K |
| Employee Count | 102 | 185 |
Dividends and yields
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Earnings Yield | 17.7% | -6.88% |
| FCF Yield | 2.96% | -0.45% |
Shares
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 27,700,900 | 44,302,700 |
| Shares Change (YoY) | 170.6% | 3.36% |
| Shares Change (QoQ) | 0.00% | 0.27% |
| Float | 2,019,100 | 37,462,700 |
| Shares Held by Insiders | 92.7% | 10.5% |
Taxes
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Income Tax | -$20.86M | $1.52M |
| Effective Tax Rate | -521.8% | 18.5% |
Scores
| Measure | Interpace Biosciences | Industry median |
|---|---|---|
| Graham Number | $4.10 | $35.97 |
| Graham Upside | -18.0% | -57.0% |
| Altman Z-Score | 0.50 | 1.95 |
| Piotroski F-Score | 5 | 5 |
| Beneish M-Score | 1.99 | -2.64 |
Calculated by StockData from Interpace Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.